What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?

Atherosclerosis Supplements

Volumn 15, Issue 2, 2014, Pages 19-25

  Santos, Raul D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Case study; Homozygous familial hypercholesterolaemia; Low density lipoprotein cholesterol; Statins; Xanthomata

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT;

APHERESIS; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; EVENT FREE SURVIVAL; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA; HUMAN; LABORATORY TEST; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); DIAGNOSTIC IMAGING; HEALTH; HYPERLIPOPROTEINEMIA TYPE II; MORBIDITY; PROCEDURES; TRENDS;

BLOOD COMPONENT REMOVAL; DIAGNOSTIC IMAGING; GLOBAL HEALTH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; MORBIDITY;

EID: 84908140315     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2014.07.003     Document Type: Article

References (27)

1. Goldstein J.K., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic basis of inherited disease 2001, 2863-2913. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223:262-268.
3. Sjouke B., Kusters D.M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2014 Feb 28, [Epubahead of print].
4. Marais A.D. Familial hypercholesterolaemia. Clin Biochem Rev 2004, 25:49-68.
5. Moorjani S., Roy M., Gagne C., Davignon J., Brun D., Toussaint M., et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec province. Arteriosclerosis 1989, 9:211-216.
6. Seftel H.C., Baker S.G., Sandler M.P., Forman M.B., Joffe B.I., Mendelsohn D., et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 1980, 281:633-636.
7. Ned R.M., Sijbrands E.J. Cascade screening for familial hypercholesterolemia (FH). PLoS Curr 2011, 3:RRN1238.
8. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
9. Cenarro A., Garcia-Otin A.L., Tejedor M.T., Solanas M., Jarauta E., Junquera C., et al. A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clin Genet 2011, 79:475-481.
10. De Castro-Oros I., Pocovi M., Civeira F. The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations. Appl Clin Genet 2010, 3:53-64.
11. Marques-Pinheiro A., Marduel M., Rabes J.P., Devillers M., Villeger L., Allard D., et al. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1. Eur J Hum Genet 2010, 18:1236-1242.
12. Kraft H.G., Lingenhel A., Raal F.J., Hohenegger M., Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000, 20:522-528.
13. Holmes D.T., Schick B.A., Humphries K.H., Frohlich J. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005, 51:2067-2073.
14. Santos R.D., Miname M.H., Martinez L.R., Rochitte C.E., Chacra A.P., Nakandakare E.R., et al. Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. Atherosclerosis 2008, 197:910-915.
15. Rallidis L., Nihoyannopoulos P., Thompson G.R. Aortic stenosis in homozygous familial hypercholesterolaemia. Heart 1996, 76:84-85.
16. Raal F.J., Pilcher G.J., Panz V.R., van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 2011, 124:2202-2207.
17. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321.
18. Bruckert E., Saheb S., Bonté J.R., Coudray-Omnés C. Daily life, experience and needs of persons suffering from homozygous familial hypercholesterolaemia: Insights from a patient survey. Atherosclerosis Supplements 2014, 15:46-51.
19. Marais A.D., Blom D.J., Firth J.C. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2002, 4:19-25.
20. Marais A.D., Raal F.J., Stein E.A., Rader D.J., Blasetto J., Palmer M., et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008, 197:400-406.
21. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panelon familial hypercholesterolemia. J Clin Lipidol 2011, 5:133-140.
22. European Medicines Agency European medicines agency confirms recommendation to suspend tredaptive, pelzontand trevaclyn 2013.
23. Gagné C., Gaudet D., Bruckert E., Ezetimibe Study G. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105:2469-2475.
24. Cuchel M., Meagher E.A., du Toit Theron H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
25. Stein E.A., Honarpour N., Wasserman S.M., Xu F., Scott R., Raal F.J. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013, 128:2113-2120.
26. Rocha V.Z., Chacra A.P., Salgado W., Miname M., Turolla L., Gagliardi A.C., et al. Extensive xanthomas and severe subclinical atherosclerosis in homozygous familial hypercholesterolemia. J Am Coll Cardiol 2013, 61:2193.
27. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50(Suppl):S172-S177.